Navigation Links
ROZEREM? Can Be A Better Option For Insomnia Patients

A recent clinical study showed that ROZEREM? (ramelteon) could be used for treating people suffering from chronic insomnia, as the medication is found to reduce the time to fall asleep in adults significantly. // It has also been found that patients who received it showed no signs of recurring or withdrawal effects.

In this placebo-controlled analysis, approximately two-thirds of patients who received 8 mg of ROZEREM experienced at least a 50 percent reduction in the time it took them to fall asleep. Study participants also experienced no rebound insomnia or withdrawal effects following discontinuation of treatment with ROZEREM. Rebound insomnia is the worsening of insomnia symptoms after a person stops taking their insomnia medications.

"These data show that ROZEREM can be effective in helping patients fall asleep faster without rebound insomnia and other withdrawal effects," said Thomas Roth, PhD, director of the Sleep Disorders and Research Center, Detroit, Mich. "This may represent another option for patients who are looking for a sleeping medication that is right for them."

About the Study In this sub-analysis of a large, double-blind, placebo-controlled study, a total of 269 adults received 8 mg of ROZEREMTM (n=138) or placebo (n=131) nightly for five weeks (35 nights). Sleep parameters were evaluated at weeks 1, 3, and 5 by using a polysomnograph. ROZEREM was replaced with placebo for the two nights following the study (nights 36 and 37) to evaluate rebound insomnia and withdrawal effects.

The primary endpoint was the percentage of patients who achieved at least 50 percent improvement in the time it took to fall asleep (latency to persistent sleep, or LPS).

Results showed that a statistically significantly greater percentage of adults with chronic insomnia treated with ROZEREM 8 mg demonstrated at least 50 percent LPS reduction compared to those who received placebo at week 1 (63 percent vs. 40 percent (P<0.001)).

Those results were sustained throughout the study (63 percent vs. 41 percent at week 3 (P<0.001); 66 percent vs. 48 percent at week 5 (P<0.005)).

The analysis revealed no evidence of rebound insomnia or withdrawal for patients taking ROZEREM as measured by the BWSQ. Adverse events were similar in both groups, with somnolence, fatigue and headache being the only events reported in 5 percent or more of patients in either group. This incidence was similar to that seen in other clinical studies.

"It is estimated that about 60 million people in the U.S. struggle with symptoms of insomnia, and this is even more significant as we learn more about the relationship between sleep disorders and other medical conditions, and the consequences of poor sleep. In this analysis of chronic insomnia patients, it was shown that approximately two-thirds had their sleep onset time cut in half – or better – with the use of ROZEREM 8 mg. This effect continued through all five weeks of the study," said Louis Mini, MD, medical director, Neuroscience at Takeda Pharmaceuticals North America, Lincolnshire, Ill. "These results represent another measure of the effectiveness of ROZEREM, and can help patients and physicians better understand this unique option for the treatment of insomnia."

ROZEREM is the first and only prescription sleep medication that has shown no evidence of abuse and dependence in clinical studies,* and as a result, has not been designated as a controlled substance. With the exception of ROZEREM, all other prescription medications indicated for insomnia are classified as Schedule IV controlled substances by the U.S. Drug Enforcement Administration. ROZEREM has a unique therapeutic mechanism of action that selectively targets two receptors located in the brain's suprachiasmatic nucleus (SCN). The SCN is known as the body's "master clock" because it regulates 24-hour, or circadian rhythms, including the sle ep-wake cycle.

The FDA approved ROZEREM in July 2005 for the treatment of insomnia, characterized by difficulty with sleep onset. It is approved for long-term use in adults.

*ROZEREM is not a controlled substance. A clinical abuse liability study showed no differences indicative of abuse potential between ROZEREM and placebo at doses up to 20 times the recommended dose (N=14). Three 35-day insomnia studies showed no evidence of rebound insomnia or withdrawal symptoms with ROZEREM compared to placebo (N=2082).

Important Safety Information

ROZEREM is indicated for the treatment of insomnia characterized by difficulty with sleep onset. ROZEREM can be prescribed for long-term use. ROZEREM should not be used in patients with hypersensitivity to any components of the formulation, severe hepatic impairment, or in combination with fluvoxamine. Failure of insomnia to remit after a reasonable period of time should be medically evaluated, as this may be the result of an unrecognized underlying medical disorder. Hypnotics should be administered with caution to patients exhibiting signs and symptoms of depression.

ROZEREM has not been studied in patients with severe sleep apnea, severe COPD, or in children or adolescents. The effects in these populations are unknown. Exercise caution if consuming alcohol in combination with ROZEREM.

ROZEREM has been associated with decreased testosterone levels and increased prolactin levels. Health professionals should be mindful of any unexplained symptoms possibly associated with such changes in these hormone levels. ROZEREM should not be taken with or immediately after a high-fat meal. ROZEREM should be taken within 30 minutes before going to bed and activities confined to preparing for bed.

The most common adverse events seen with ROZEREM that had at least a 2% incidence difference from placebo were somnolence, dizziness, and fatigue.

--EurekAle rt
'"/>




Related medicine news :

1. Better prostate cancer detection
2. Better Treatment for obesity
3. For a Better Memory
4. Baby Talk Better Than Adult Speech
5. Drug Combo Works Better for children with ADHD, Tics
6. Better skin with lasers
7. Better diabetes treatment promises Vanadium
8. Better Prostate Cancer Test
9. Better Drug for Heart Transplant
10. Better Diet Even Late in Life May Prolong It
11. Better Care Required for Breast Cancer Survivors
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2017)... ... , ... The Anaheim Hills office accelerates and supports FNCC’s growth and further ... sales professionals over the past 6 months and is continuing to recruit new talent ... course of 2017. , “This new office is a direct result of our ...
(Date:3/27/2017)... ... 2017 , ... ?Grow Healthy Vending LLC announced today that ... itself and 1800 Vending DBA Healthy You Vending. (Civil No. 1:14-CV-00121-CW/ United States ... that we have now reached a settlement agreement regarding the ongoing lawsuits between ...
(Date:3/27/2017)... ... 27, 2017 , ... The homeowner improvement and repair market is expected to ... unlicensed contractors for renovations is also on the rise. Per a 2017 report, 13% ... those, 42% failed to use a licensed contractor.(2) The risks associated with improper renovations—especially ...
(Date:3/25/2017)... Square, PA (PRWEB) , ... March 25, 2017 , ... ... priority as a public relations partner. , All through the year, Garden Media ... and press releases, working with key influencers and pitching client’s key messages ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... at the same time by providing Prehospital Trauma Life Support (PHTLS) course scholarships ... world’s premier prehospital trauma education developed in cooperation with the American College of ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... and PUNE, India , March 24, 2017 ... "Spine Bone Stimulators Market: Global Opportunity Analysis and Industry Forecast, 2014-2022," the spine ... to reach $724 million by 2022, growing at a CAGR of 3.6% during ... ... Allied Market Research Logo ...
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets has announced ... Growth and Demand Forecast to 2022" report to their offering. ... The global wound care market ... at a CAGR of 6.7% during 2016-2022 Among the various ... largest share in the global market in 2015. Among the various applications, ...
(Date:3/24/2017)... NEW YORK , March 24, 2017 /PRNewswire/ ...  a leading organization within medical affairs in the ... as the chair of a newly formed ... additional board members to form the first ever ... For more information about the ACMA, ...
Breaking Medicine Technology: